Experimental mallory body formation is accompanied by modulation of the expression of multidrug-resistance genes and their products

Hepatology

Volumn 24, Issue 1, 1996, Pages 248-252

  Preisegger, Karl Heinz ^a,b   Stumptner, Conny ^a   Riegelnegg, Doris ^a   Brown, Paul C ^b   Silverman, Jeffrey A ^b   Thorgeirsson, Snorri S ^b   Denk, Helmut ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; GENE PRODUCT; GLYCOPROTEIN P; GRISEOFULVIN; KERATIN; MESSENGER RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ALCOHOL LIVER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; GENE EXPRESSION REGULATION; IMMUNOFLUORESCENCE MICROSCOPY; INTERMEDIATE FILAMENT; MALE; MALLORY BODY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029888189     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008707270     Document Type: Article

References (50)

1. Denk H, Franke WW, Kerjaschki D, Eckersdorfer R. Mallory bodies in experimental animals and in man. Int Rev Exp Pathol 1979;20:77-82.
2. Denk H, Gschnait F, Wolff K. Hepatocellular hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest 1975;32:773-777.
3. Yokoo H, Harwood TR, Racker D, Arak S. Experimental production of Mallory bodies by diet containing 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Gastroenterology 1982;83:109-113.
4. Denk H, Franke WW, Dragosics B, Zeiler I. Pathology of the cytoskeleton of liver cells: demonstration of Mallory bodies (alcoholic hyalin) in murine and human hepatocytes by immunofluorescence microscopy using antibodies to cytokeratin polypeptides from hepatocytes. HEPATOLOGY 1991;1:9-20.
5. Denk H, Lackinger E, Vennigerholz F. Pathology of the cytoskeleton of hepatocytes. Prog Liver Dis 1986;8:237-245.
6. Denk H, Franke WW, Eckersdorfer R, Schmid E, Kerjaschki D. Formation and involution of Mallory bodies ("alcoholic hyalin") in murine and human liver as revealed by immunofluorescence microscopy with antibodies to prekeratin. Proc Natl Acad Sci U S A 1979;76:4112-4116.
7. Zatloukal K, Denk H, Spurej G, Lackinger E, Preisegger KH, Franke WW. High molecular weight component of Mallory bodies detected by a monoclonal antibody. Lab Invest 1990;62:427-434.
8. Preisegger KH, Zatloukal K, Spurej G, Denk H. Changes of cytokeratin filament organization in human and murine Mallory body-containing livers as revealed by a panel of monoclonal antibodies. Liver 1991;11:300-309.
9. Preisegger KH, Zatloukal K, Spurej G, Riegelnegg D, Denk H. Common epitopes of human and murine Mallory bodies and Lewy bodies as revealed by a neurofilament antibody. Lab Invest 1992;66:193-199.
10. Zatloukal K, Denk H, Lackinger E, Rainer I. Hepatocellular cytokeratins as substrates of transglutaminases. Lab Invest 1989;61:603-608.
11. Lowe J, Blanchard A, Morell K, Lennox G, Reynolds L, Billet M, Landon M, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 1988;155:9-15.
12. Mayer RJ, Lowe J, Landon M, McDermott H, Tuckwell J, Doherty F, Laszlo L. Ubiquitin and the lysosomal system: molecular pathological and experimental findings. In: Maresca B, Linquist S, eds. Heat Shock. Berlin, New York: Springer, 1992:299-315.
13. Zatloukal K, Spurej G, Rainer I, Lackinger E, Denk H. Fate of Mallory body-containing hepatocytes: disappearance of Mallory bodies and restoration of the hepatocytic intermediate filament cytoskeleton after drug withdrawal in the griseofulvin-treated mouse. HEPATOLOGY 1990;11:652-661.
14. Woltsche M, Zatloukal K, Denk H. Enzyme-histochemical studies of griseofulvin-intoxicated mouse livers. Liver 1991;11:231-240.
15. Thorgeirsson SS, Huber BE, Sorell S, Fojo A, Pastan I, Gottesman MM. Expression of the multidrug resistant gene in hepatocarcinogenesis and regenerating liver. Science 1987;236:1120-1122.
16. Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers CE, et al. Carcinogen-induced mdr overexpress ion is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci U S A 1987;84:7701-7705.
17. Teeter LD, Becker FF, Chisari FV, Li D, Kuo MT. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990;10:5728-5735.
18. Teeter LD, Petersen DD, Nebert DW, Kuo MT. Murine mdr-1, mdr-2, and mdr-3 gene expression: no coinduction with Cyp 1a-1 and Nmo-1 genes in liver by 2,3,7,8-tetrachlorodibenzo-p-dioxin. DNA Cell Biol 1991;10:433-441.
19. Schrenk D, Gant TW, Preisegger KH, Silverman JA, Marino PA, Thorgeirsson SS. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. HEPATOLOGY 1993;17:854-860.
20. Kuo MT, Zhao JT, Teeter LD, Ikegushi M, Chisari FV. Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1 gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ 1992;3:531-540.
21. Gant TW, Silverman JA, Bisgaard HC, Burt RK, Marino PA, Thorgeirsson SS. Regulation of 2-Acetylaminofluorene- and 3-Methylcholanthrene-mediated induction of multidrug resistance and cytochrome P450IA gene family expression in primary hepatocyte cultures and rat liver. Mol Carcinog 1991;4:499-509.
22. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455: 152-162.
23. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990;10:1652-1663.
24. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
25. Gottesman MM, Goldstein LJ, Fojo A, Galski H, Pastan I. Expression of the multidrug resistance gene in human cancer. In: Roninson IB, ed. Molecular and cellular biology of multidrug resistance in tumor cells. New York: Plenum, 1991:291-308.
26. Ng WF, Sarangi F, Zastawany RL, Veinot-Drebot L, Ling V. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989;9: 1224-1232.
27. Gros P, Buschman E. The mouse multidrug resistance family: structural and functional analysis. Int Rev Cytol 1993;137:169-197.
28. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 1987;84:3004-3008.
29. Silverman JA, Raunio H, Gant TW, Thorgeirsson SS. Cloning and characterization of a member of the rat multidrug resistance gene family. Gene 1991;106:229-236.
30. Brown PC, Thorgeirsson SS, Silverman JA. Cloning and regulation of the rat mdr2 gene. Nucleic Acids Res 1993;21:3885-3891.
31. van der Bliek AM, Borst P. Multidrug resistance. Adv Cancer Res 1989; 52:165-203.
32. Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986;5:25-46.
33. Smit JJ, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-462.
34. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994;77:1071-1081.
35. Thiebault F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal tissues. Proc Natl Acad Sci U S A 1987;84:7735-7738.
36. Cordon-Cardo C, O'Brian JP, Casals D, Boccia J, Bertino JR. Immunoanatomic and immunopathologic expression of the multidrug resistance gene product. Cancer Cells 1989;9:87-93.
37. Hsu I-HS, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 1989;264:12053-12062.
38. Buschman E, Arceci RJ, Croop JM, Che M, Arias IM, Housman DE, Gros P. Mdr2 encodes a P-glycoprotein expressed in bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 1992;25:18093-18099.
39. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of Gp 170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989;264:11693-11698.
40. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989;9: 1345-1350.
41. Arias IM. Multidrug resistance genes, P-glycoprotein and the liver. HEPATOLOGY 1990;12:159-165.
42. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:152-156.
43. Childs S, Lin Yeh R, Georges E, Ling V. Identification of a sister gene to P-glycoprotein. Cancer Res 1995;55:2029-2034.
44. Sambrook J, Fritsch EF, Maniatis T, eds. Molecular cloning, 2nd ed. Vol 1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989;7.43-7.45.
45. Hurst EW, Pagets GE. Protoporphyrin, cirrhosis and hepatoma in the livers of mice given griseofulvin. Br J Dermatol 1963;75:10-102.
46. Denk H, Eckersdorfer R, Gschnait F, Konrad K, Wolff K. Experimental induction of hepatocellular hyalin (Mallory bodies) in mice by griseofulvin treatment. Light microscopic observations. Lab Invest 1976;35:377-381.
47. Mauad TH, van Nieuwkerk CMJ, Dingemans KP, Smit JJM, Schinkel AH, Notenboom RGE, van den Bergh Weerman MA, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994;145:1237-1245.
48. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
49. Denk H, Krepler R, Lackinger E, Artlieb U, Franke WW. Biochemical and immunocytochemical analysis of the intermediate filament cytoskeleton in human hepatocellular carcinomas and in hepatic neoplastic nodules in mice. Lab Invest 1982;46:584-596.
50. Kuo MT. Expression of multidrug resistance (P-glycoprotein) genes in liver cancers: a molecular example of the convergence theory in hepatocarcinogenesis? Mol Carcinog 1993;7:73-75.